TN2012000084A1 - Fused heterocyclic ring derivative and use thereof - Google Patents

Fused heterocyclic ring derivative and use thereof

Info

Publication number
TN2012000084A1
TN2012000084A1 TNP2012000084A TN2012000084A TN2012000084A1 TN 2012000084 A1 TN2012000084 A1 TN 2012000084A1 TN P2012000084 A TNP2012000084 A TN P2012000084A TN 2012000084 A TN2012000084 A TN 2012000084A TN 2012000084 A1 TN2012000084 A1 TN 2012000084A1
Authority
TN
Tunisia
Prior art keywords
heterocyclic ring
fused heterocyclic
ring derivative
smo
disclosed
Prior art date
Application number
TNP2012000084A
Other languages
English (en)
Inventor
Satoshi Sasaki
Yuta Tanaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TN2012000084A1 publication Critical patent/TN2012000084A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TNP2012000084A 2009-08-26 2012-02-21 Fused heterocyclic ring derivative and use thereof TN2012000084A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009195770 2009-08-26
JP2010015644 2010-01-27
PCT/JP2010/064413 WO2011024872A1 (ja) 2009-08-26 2010-08-25 縮合複素環誘導体およびその用途

Publications (1)

Publication Number Publication Date
TN2012000084A1 true TN2012000084A1 (en) 2013-09-19

Family

ID=43627972

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000084A TN2012000084A1 (en) 2009-08-26 2012-02-21 Fused heterocyclic ring derivative and use thereof

Country Status (24)

Country Link
US (1) US8907089B2 (enExample)
EP (1) EP2471790B1 (enExample)
JP (1) JP5599802B2 (enExample)
KR (1) KR20120078703A (enExample)
CN (1) CN102574851A (enExample)
AU (1) AU2010287492A1 (enExample)
BR (1) BR112012004134A2 (enExample)
CA (1) CA2771833A1 (enExample)
CL (1) CL2012000461A1 (enExample)
CR (1) CR20120095A (enExample)
DO (1) DOP2012000048A (enExample)
EA (1) EA201270311A1 (enExample)
EC (1) ECSP12011747A (enExample)
GE (1) GEP20146075B (enExample)
IL (1) IL218323A0 (enExample)
IN (1) IN2012DN02069A (enExample)
MA (1) MA33589B1 (enExample)
MX (1) MX2012002419A (enExample)
NZ (1) NZ598749A (enExample)
PE (1) PE20121326A1 (enExample)
SG (1) SG178504A1 (enExample)
TN (1) TN2012000084A1 (enExample)
WO (1) WO2011024872A1 (enExample)
ZA (1) ZA201201795B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2002012189A1 (en) 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005081960A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057469A1 (en) * 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
CA2690953C (en) 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
JP4685891B2 (ja) 2008-02-19 2011-05-18 株式会社ハネックス 分離装置
CN102015705B (zh) * 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
JP2010015644A (ja) 2008-07-04 2010-01-21 Fujitsu Ltd スピンドル機構、電磁変換特性評価機、および情報記憶装置
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent

Also Published As

Publication number Publication date
EA201270311A1 (ru) 2012-09-28
SG178504A1 (en) 2012-04-27
IL218323A0 (en) 2012-04-30
WO2011024872A1 (ja) 2011-03-03
CL2012000461A1 (es) 2012-10-05
MA33589B1 (fr) 2012-09-01
US8907089B2 (en) 2014-12-09
ZA201201795B (en) 2013-05-29
BR112012004134A2 (pt) 2017-06-20
EP2471790A1 (en) 2012-07-04
PE20121326A1 (es) 2012-10-11
AU2010287492A1 (en) 2012-03-29
DOP2012000048A (es) 2012-05-15
MX2012002419A (es) 2012-04-19
US20120220570A1 (en) 2012-08-30
NZ598749A (en) 2013-01-25
JP5599802B2 (ja) 2014-10-01
JPWO2011024872A1 (ja) 2013-01-31
EP2471790B1 (en) 2015-03-18
ECSP12011747A (es) 2012-05-30
IN2012DN02069A (enExample) 2015-08-21
CR20120095A (es) 2012-06-26
CA2771833A1 (en) 2011-03-03
EP2471790A4 (en) 2013-07-31
CN102574851A (zh) 2012-07-11
GEP20146075B (en) 2014-04-10
KR20120078703A (ko) 2012-07-10

Similar Documents

Publication Publication Date Title
TN2012000401A1 (en) Heterocyclic compound
TN2012000153A1 (en) Heterocyclic sulfonamide derivatives useful as mek inhibitors
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PH12014500599B1 (en) Protein kinase inhibitors
MX2012006491A (es) Derivados de oxazina.
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MX358679B (es) Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MX2012013467A (es) Compuestos macrociclicos como inhibidores de trk cinasa.
MX2010008686A (es) Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo.
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MY150075A (en) Novel phosphodiesterase inhibitors
IN2014DN07509A (enExample)
TN2012000092A1 (en) Therapeutic agent for mood disorders
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof